IceCure Medical Ltd. (ICCM) announced on Monday that it has received marketing authorization from the U.S. Food and Drug Administration (FDA) for its latest innovation, the XSense Cryoablation System with CryoProbes.
The XSense system and its cryoprobes have been approved for all previously authorized indications of the ProSense system. These include use in general minimally invasive cryoablation procedures across various specialties such as general surgery, dermatology, neurology (including cryoanalgesia), thoracic surgery, ENT, gynecology, oncology, proctology, and urology.
This advanced system is engineered to eliminate tissue through the application of extreme cold, targeting conditions like fibroadenomas, kidney tissue abnormalities, liver metastases, tumors, skin lesions, and warts.
